Sanofi outbids Novo with €45 per share offer for Ablynx, total of €3.8bn
Public Belgian biotech Ablynx NV agreed to be acquired by Sanofi, which offered €45 per share ($59.92; a 37% premium) for a fully diluted equity value of €3.8bn ($5.1bn). The deal trumps an offer made earlier this month by Novo, which bid €28 per share plus CVRs for a total value of €2.3bn. Ablynx shareholders repeatedly rejected Novo’s advances, and Novo has stated that it will not make a revised offer.
- Drug Delivery
- Large Molecule
- Full Acquisition
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com